Background. Oritavancin (ORI) is under regulatory review in the USA and Europe for the treatment of acute bacterial skin and skin structure infections (SSSI) caused by Gram-positive pathogens. The ORI activity was assessed against contemporary isolates causing SSSI.
Methods. 8,428 isolates from documented SSSI were collected from 27 sites in the USA and 34 sites in Europe, Israel and Turkey as part of the SENTRY Antimicrobial Surveillance Program (2012 Program ( -2013 . Bacteria were identified by standard algorithms and MALDI-TOF. Susceptibility testing was performed by CLSI methods (M07-A9); interpretation of MIC results used CLSI (2014) and EUCAST (2014) 
criteria
Results. ORI had MIC 50/90 values of 0.03/0.06 µg/ml against S. aureus, which were ≥8-fold lower than those obtained for vancomycin (VAN; MIC 50/90 , 1/1 µg/ml), daptomycin (DAP; MIC 50/90 , 0.25/0.5 µg/ml) or linezolid (LZD; MIC 50/90 , 1/1 µg/ml). (MIC 50/90 , 0.03/0.12 µg/ml) against VanA strains. However, ORI MIC values against VanA E. faecium were 8-to -64 lower than active (100% susceptible) comparators (DAP, MIC 50/90 , 2/4 µg/ml; and LZD, MIC 50/90 , 1/1 µg/ml). ORI had potent activity against S. pyogenes (MIC 50/90 , 0.03/0.12 µg/ml), S. agalactiae (MIC 50/90 , 0.03/ 0.06 µg/ml) and the S. anginosus group (MIC 50/90 , 0.008/0.015 µg/ml), with slightly higher MIC results against S. dysgalactiae (MIC 50/90 , 0.06/0.25 µg/ml).
Conclusion. ORI had potent activity in vitro against this contemporary collection of Gram-positive isolates causing SSSI. These results benchmark ORI activity prior to becoming clinically available.
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